Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) major shareholder Sanofi acquired 166,415 shares of the stock in a transaction that occurred on Thursday, August 24th. The stock was acquired at an average price of $480.93 per share, with a total value of $80,033,965.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Sanofi also recently made the following trade(s):
- On Friday, June 2nd, Sanofi purchased 136,050 shares of Regeneron Pharmaceuticals stock. The shares were purchased at an average price of $478.17 per share, for a total transaction of $65,055,028.50.
Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.54% during trading on Friday, hitting $477.80. The company’s stock had a trading volume of 531,653 shares. The firm’s 50 day moving average price is $487.65 and its 200-day moving average price is $435.10. The company has a market cap of $50.66 billion, a PE ratio of 47.93 and a beta of 1.66. Regeneron Pharmaceuticals, Inc. has a 52 week low of $325.35 and a 52 week high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. During the same quarter last year, the business posted $2.82 earnings per share. The firm’s revenue was up 21.2% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in REGN. National Pension Service boosted its stake in Regeneron Pharmaceuticals by 10.8% in the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after buying an additional 6,481 shares in the last quarter. Grandfield & Dodd LLC boosted its stake in Regeneron Pharmaceuticals by 1.1% in the first quarter. Grandfield & Dodd LLC now owns 1,497 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 17 shares in the last quarter. Princeton Capital Management Inc. boosted its stake in Regeneron Pharmaceuticals by 6.7% in the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after buying an additional 157 shares in the last quarter. CIBC World Markets Inc. boosted its stake in Regeneron Pharmaceuticals by 2,190.6% in the first quarter. CIBC World Markets Inc. now owns 21,784 shares of the biopharmaceutical company’s stock valued at $8,442,000 after buying an additional 20,833 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its stake in Regeneron Pharmaceuticals by 3.4% in the first quarter. Oppenheimer & Co. Inc. now owns 5,808 shares of the biopharmaceutical company’s stock valued at $2,251,000 after buying an additional 189 shares in the last quarter. Hedge funds and other institutional investors own 67.16% of the company’s stock.
A number of research firms have commented on REGN. BidaskClub upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Morgan Stanley restated an “equal weight” rating and set a $450.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research note on Wednesday, August 16th. They set an “outperform” rating and a $605.00 price target on the stock. J P Morgan Chase & Co restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Finally, Leerink Swann restated a “positive” rating and set a $552.00 price target (down from $580.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 15th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $495.59.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
